Clinical dosage of toxic and essential elements in blood is well established; however, the collection method nowadays is still by venipuncture. This method has several drawbacks and is not suited for everyone, especially pediatric patients. Fortunately, volumetric absorptive microsampling (VAMS®) has been shown to bring significant advantages over venepuncture for blood sampling.
​
This webinar provides an overview of the development and validation as well as the performance of a method for the quantification by ICP-MS/MS of various toxic and essential elements in blood collected on VAMS tips.
​
Of particular interest to analytical chemists, research scientists, epidemiologists, health professionals, and those working in or with health authorities.​​​​​​​​​​​​​​​
Speakers
Supervisor of Trace Metals Team, Centre de toxicologie du Québec – Institut national de santé publique du Québec, Canada
​
Dr Cirtiu completed his PhD at the Université de Sherbrooke (2007) and continued specializing in materials and analytical chemistry with post-docs at UQAM and McGill University. He joined the Centre de Toxicologie du Québec at Institut National de Santé Publique de Québec in 2011 as an analytical development chemist. In January 2013, he was named supervisor of trace metals team. His research activities are oriented towards the development of new technologies and methodologies for the analysis of emerging products (nanoparticles, metals, rare earths elements) in order to advance knowledge in terms of toxicology and human biomonitoring. His scientific contribution can be summarized as follow: 30 articles, 2 patents, 43 oral communications and 29 posters.
Moderator
Director Spooner Bioanalytical Solutions & Chair Patient Centric Sampling Interest Group
​
Neil is the Co-founder and Chair of the PCSIG. He is also the Founder of Spooner Bioanalytical Solutions, helping companies to integrate biological fluid microsampling, and patient centric sampling and analysis into workflows. He also works with organizations to develop technologies and introduce them to the market. Neil also assists organizations with their understanding of emerging trends in the pharmaceutical industry and bioanalysis. Neil is a Senior Visiting Research Fellow at the University of Hertfordshire, Editor in Chief of the journal, Bioanalysis and Chair of the Reid International Bioanalytical Forum. He has published over 70 peer reviewed manuscripts and delivered over 50 podium presentations.​​​​​​​
IN ASSOCIATION WITH
OUR SPONSORS
Alturas Analytics provides expert GLP & non-GLP LC-MS/MS and GC-MS/MS bioanalytical and PK/TK analysis services of small and large molecules in any matrix for discovery through Phase IV clinical trials.
​
Capitainer: Dried blood spots (DBS) is now quantitative with volumetric control through our microfluidic qDBS technology solution. Precision, accuracy, sample protection and ease of use both at sampling and in the lab are key features for us in all product development.
​
Charles River Laboratories are a leading drug discovery and development contract research organisation providing a broad spectrum of laboratory and data science support to the Clinical development industries. This includes bioanalytical chemistry, immunology, biomarker services, immunoassay, genomics, vaccine development and ADME services. With over 1000 dedicated laboratory colleagues across a global footprint and expertise in traditional and advanced modalities, Charles River Laboratories are well placed to leverage scale and scope to support Clinical programmes carried out anywhere in the world.
​
Genentech: Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit gene.com.
​
GSK: We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.
​
MSD/Merck: We use the power of leading-edge science to save and improve lives around the world.
​
Q  Solutions is a leading drug discovery and development laboratory services organization providing innovative solutions that encompass broad central laboratory and specialty biomarker services, including genomics, immunoassays, flow cytometry, anatomic pathology, precision medicine assays, vaccine assays, ADME and bioanalytical along with extensive offerings in antibody drug discovery, biomarker discovery, and decentralized clinical trial lab solutions. Through the Decentralized Clinical Trials group, Q  Solutions is at the forefront of patient-centric sampling, offering a variety of self-collection methodologies and is validating multiple assays using micro-samples that are self-collected by study participants.
Â
RedDrop Dx: Next generation blood sampling solutions.
​
Roche:Â Doing now what patients need next.
​
Takeda:Â We exist to create better health for people and a brighter future for the world. While the science and technology we advance are constantly evolving, our ambition remains. We move science forward, so we can transform more lives.
​
Tasso, is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time.
​
Veloxity Labs, is a CRO focused on LC-MS bioanalysis. Our company is employee owned and operated, and offers start-up times and turn-around times in days by maintaining 80% capacity.
​
Waters Corporation, a global leader in analytical instruments, consumables, and software, has pioneered innovations in chromatography, mass spectrometry, and thermal analysis serving the life sciences market for more than 60 years. Waters Corporation aligns with PCSIG's mission, supporting collaboration among diverse stakeholders to advance pharmaceutical medicines development and elevating healthcare outcomes and decision-making through analytical innovation and precision.
​
YourBio Health, makers of the TAP® device, was founded by Flagship Pioneering in 2007. TAP® is the world’s first push button collection device. Our technology allows a patient blood sample to be collected from any location without the pain of a fingerstick or need for traditional phlebotomy. We enable the decentralization of clinical trials and access to companies who offer wellness testing to consumers. Our patient-centric device is virtually painless, easy-to-use, and enables the collection of a blood specimen from any setting – clinical or in-home. We eliminate barriers to blood collection.